Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00258_DB01583_nanopub.RASU81vt5JVbeSVEidWREHVXRez7iZf-dhs5feCsdYjrg#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00258_DB01583 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00258_DB01583 label "DDI between Calcium Acetate and Liotrix - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. [drugbank_resource:DB00258_DB01583]" assertion.
- drugbank_resource:DB00258_DB01583 identifier "drugbank_resource:DB00258_DB01583" assertion.
- drugbank_resource:DB00258_DB01583 title "DDI between Calcium Acetate and Liotrix - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased." assertion.
- drugbank:DB00258 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00258_DB01583 assertion.
- drugbank:DB01583 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00258_DB01583 assertion.